Company intelligence / Profile preview
Lunai Bioworks
Los Angeles, California, United Statesrenovarogroup.com ↗
- Ownership
- Public · LNAI
- Employees
- ~25
- Development stage
- Other
01
Overview
All programs are in the pre-clinical stage; advanced preclinical work in cancer (pancreatic, breast) and diagnostics, with investigational cell therapy and AI biomarker technologies. No clinical trial results published to date.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Genetically modified cellular therapyImmune-therapyAllogeneic dendritic cell therapyArtificial intelligence platform (diagnostics)
- Industry
- Biotech
02
Drug pipeline
21 assets20 more assets in the full pipeline.
03
Partnerships
Nebul (strategic cancer detection collaboration)
04
Financials
- Market cap
- $829.7K
- Total revenue
- $52K
- Enterprise value
- $-374.4M
Beyond the preview
Go deeper on Lunai Bioworks.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lunai Bioworks.